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Abstract 
 
Alzheimer’s disease (AD) is a tauopathy characterised by pathological fibrillisation of tau protein to form 
the paired helical filaments (PHFs) which constitute neurofibrillary tangles. The methylthioninium (MT) 
moiety reverses the proteolytic stability of the PHF core and is in clinical development for treatment of 
AD in a stable reduced form as leuco-MT (LMT). It has been hypothesised that MT acts via oxidation of 
cysteine residues which is incompatible with activity in the predominantly reducing environment of living 
cells. We have shown recently that the PHF-core tau unit assembles spontaneously in vitro to form PHF-
like filaments. Here we describe studies using circular dichroism, SDS-polyacrylamide gel 
electrophoresis, transmission electron microscopy and site-directed mutagenesis to elucidate the 
mechanism of action of the MT moiety. We show that MT inhibitory activity is optimal in reducing 
conditions, that the active moiety is the reduced LMT form of the molecule, and that its mechanism of 
action is cysteine-independent. (152 words) 
 
Keywords: tau; methylthioninium; hydromethylthionine; neurofibrillary tangles; circular dichroism; 
electron microscopy 
Highlights:  
 Paired helical filaments (PHF) composed of tau form in Alzheimer’s disease. 
 PHF formation is a target for treatment.  
 Methylthioninium (MT) inhibits spontaneous assembly of a core tau unit into PHFs.  
 MT acts optimally in the reduced form as Leuco-MT (LMT) and not via cysteine oxidation.  
 LMT is effective at much lower doses than the oxidised form of MT in clinical trials.  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Introduction 
Tau protein plays a role in the assembly and stability of microtubules in the cytoplasm [1-3] and in the 
stabilisation of heterochromatin in the nucleus [4]. Tau is encoded by the MAPT gene on chromosome 17 
and alternative splicing generates six major isoforms of tau in the central nervous system, three with four 
imperfect repeat regions and three with three repeats. In Alzheimer’s disease (AD) and a group of 
neurodegenerative diseases, known collectively as tauopathies, tau accumulates abnormally in the brain. 
In AD, tau protein self-assembles to form paired helical filaments (PHFs) and straight filaments (SFs) 
which constitute the neurofibrillary tangles within neurons and dystrophic neurites in brain. The tau 
species isolated from proteolytically stable PHF-core preparations from AD brain tissue comprise a 
mixture of fragments derived from both 3- and 4-repeat isoforms, but restricted to the equivalent of three 
repeats, with an N-terminus at residues Ile-297 or His-299 (4-repeat numbering) and the C-terminus at 
residue Glu-391, or at homologous positions in other species [5, 6]. The same segment of the molecule, 
encompassing residues 306–378, has been confirmed as constituting the core of the PHF using cryo-
electron microscopy analysis of PHFs extracted from AD brain tissue [7] and a homologous core 
fragment from 3-repeat tau been identified in the filaments found in some forms of Frontotemporal 
Dementia (FTD)[8].  
 
Since tau aggregation pathology is closely associated with cognitive decline [9-18], treatment based on 
the use of tau aggregation inhibitors (TAIs) offers a potentially promising therapeutic approach for AD 
[19]. We have shown previously that the methylthioninium (MT) moiety, which can exist in oxidised 
(MT
+
, Fig 1d) and reduced leuco-MT (LMT, Fig 1e) forms, is able to act as a tau aggregation inhibitor in 
cell-free [20, 21], cell-based [20] and tau transgenic mouse models of tau aggregation [22]. When applied 
to preparations of proteolytically stable PHFs isolated from AD brain, MT reverses the proteolytic 
stability of the constituent tau protein [21] at protein:MT molar ratios upwards of approximately 1:0.1 
[20].  
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Attempts to understand the mechanism of action of the MT moiety have been based so far on heparin-
induced filament formation using the repeat-domain tau fragments known as K19 and K18 [23]. Heparin 
induced filaments formed by tau have been contain a heterogeneous core structure which is different from 
AD PHF [24]. The three-repeat K19 fragment, which is nearest to the core tau unit of the PHF, 
encompasses repeats R1, R3 and R4 (Gln-244 - Glu-372, without R2). It includes the additional R1 at the 
N-terminus which is not present in PHF core tau unit isolated from AD brain tissues [25] or in the protein 
used in the present studies. When included during heparin-induced assembly of the K19 fragment (which 
contains a single cysteine at 322), the MT moiety has been reported to produce an intermolecular 
disulphide cross-linked dimer in non-reducing (but not in reducing) conditions [23]. Such dimers have 
been shown to enhance filament formation, and this has been taken to be the explanation for the relative 
lack of inhibitory effect of MT on K19 fibrillisation in either oxidising or reducing conditions [23]. The 
K18 fragment containing repeats R1, R2, R3 and R4 differs even more from the PHF core tau unit, with 
an extra 54 residues at the N-terminus relative to the PHF core tau unit and contains two cysteine 
residues. The MT moiety inhibits heparin-induced fibrillisation of the K18 fragment only in non-reducing 
conditions, and this effect requires formation of an intramolecular disulphide cross-link which renders the 
K18 peptide assembly incompetent [23]. Therefore, it has been hypothesised that the mechanism of action 
of tau aggregation inhibition by the MT moiety is via cysteine oxidation [23, 26]..  
 
We have reported recently that the truncated tau fragment corresponding to one of the species isolated 
from proteolytically stable PHF preparations (residues Ile-297 – Glu-391), and referred to as “dGAE” [25, 
27], has quite different assembly properties in vitro from those reported using K19 and K18 fragments. 
The dGAE fragment does not require heparin to induce fibrillisation. It assembles spontaneously in 
physiological conditions in vitro into filaments that closely resemble native PHFs and SFs from AD brain 
morphologically [28]. These in vitro assembled PHFs display a characteristic β-sheet structure by circular 
dichroism and X-ray fibre diffraction analysis. Previous studies, using a 1-383 tau fragment, have 
suggested that heparin induced assembly is enhanced by disulphide formation and reduced by the 
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substitution of Cys322A [29]. However, in contrast to the behaviour of the K19, K18 and 1-383 
fragments in vitro, dGAE filament assembly is substantially enhanced in reducing conditions, or with 
replacement of the single cysteine residue at position 322 with alanine. This suggests that the assembly of 
the PHF core tau unit is unrelated to cysteine cross-linking and calls into question the cysteine oxidation 
hypothesis as the explanation of the mechanism of action of the MT moiety. We have applied a range of 
structural approaches aiming to understand the mechanism of action of the MT moiety as this applies to 
the PHF core tau unit. We show that inhibitory activity is optimal in reducing conditions, that the active 
moiety responsible for inhibition of tau aggregation is the reduced LMT form of the molecule, and that 
the mechanism of action is cysteine-independent. A stable reduced form of MT (leuco-methylthioninium 
bis(hydromethanesulphonate), “LMTM”, USAN name “hydromethylionine mesylate”) is currently in 
Phase 3 clinical development for treatment of AD and FTD. The structures of MT+ and LMT are shown 
in Figure 1a and b.  
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Results 
Heparin binds directly to the MT moiety 
Heparin has been used previously to study the mechanism of action of the MT moiety [23, 26]. A CD 
spectrum of MT incubated with heparin at a heparin:MT molar ratio of 1:3 is shown in Fig. 1c. A very 
prominent and broad CD peak was observed at 300 and 340 nm that was absent when either heparin or 
MT were incubated alone (Fig 1c). This peak therefore arises as a result of an association between the MT 
moiety and heparin.  
 
dGAE assembly in the presence of MT in non-reducing conditions  
dGAE assembles spontaneously into filaments without a requirement for heparin [28]. When MT was 
included during dGAE assembly in non-reducing conditions at tau:MT ratios ranging from 1:0.1 to 1:10, 
circular dichroism (CD) spectra showed an increased random coil content (minimum shown at 200 nm) in 
the supernatant (Fig. 2b) and a corresponding reduction in fibrillar -sheet structure in the pellet (red-
shifted minimum at 230 nm [28] (Fig. 2a). The appearance of a red shifted peak for -sheet is commonly 
observed for elongated -sheets that appear in amyloid fibrils [30, 31]. In addition, a new CD peak at 300 
nm, with an accompanying shoulder at 250 nm, appeared in the pellet fraction (Fig. 2a). To explore the 
origin of this new peak, CD spectra were collected on the pellet of centrifuged preformed fibrils (prepared 
in non-reducing conditions) before and immediately after MT was added. The spectra showed reduction 
of the signal at 230 nm and a very weak, broad maximum at 280-300 nm (Fig. S1).  
 
In the absence of MT, Coomassie-stained SDS-PAGE gels showed the presence of species with 10 and 
12kDa mobilities in the supernatant and that the bulk of the protein sedimented in a low-speed pellet that 
was dominated by a dimer having gel mobility of 24 kDa, as well as a 12 kDa monomer and a 48 kDa 
oligomer [28]. When assembly was conducted in the presence of MT, there was a slight reduction in the 
12 and 24 kDa species in the pellet at a tau:MT molar ratio of 1:0.2, although generally the intensity of 
bands remained similar for increasing ratios of MT (Fig. 2c).  
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There was no clear effect of the MT moiety on the appearance of the short filaments assembled in non-
reducing conditions by TEM. Clumping of short filaments into large fibrillar aggregates and some 
elongated filaments became apparent at high molar ratios (1:5 and 1:10) (Fig. 2d). 
 
dGAE assembly in the presence of MT in reducing conditions  
We have shown previously that assembly of dGAE is substantially enhanced in reducing conditions 
(DTT, 10 mM) [28]. In order to examine the effect of MT during assembly in reducing conditions, we 
first showed that the CD spectrum of MT itself was unaffected by the presence of DTT (Fig 1d). Using a 
combination of UV spectroscopy and mass spectrometry we showed that the predominant MT species 
present in the reducing conditions used is the reduced form, LMT. By contrast, the predominant species in 
non-reducing conditions is the oxidised form, MT
+
 (Fig. S2a). UV spectrometry showed the presence of 
MT
+
 in the absence of DTT with a prominent absorbance peak at 600 and 680 nm as well as a peak at 300 
nm. DTT alone gave a strong peak at 200-210 nm (Fig. S2a,b). DTT with MT resulted in a sharp peak at 
approximately 250 nm with a small shoulder at 300 nm (Fig. S2a). The MT
+
 specific peak at 600-680 was 
absent, showing that under reducing conditions, most of the MT is present as LMT. Mass spectrometry 
confirmed the presence of MT
+
 following ionisation (Fig. S2d). 
 
dGAE assembly in the presence of MT under reducing conditions resulted in a clear concentration-
dependent loss of β-sheet signal in the CD spectrum of the pellet and a corresponding increase in random 
coil in the supernatant (Figure 3a and b). The 300/250 nm peaks were more evident in the CD spectrum 
from the pellet, and were maximal at a tau:MT molar ratio of 1:0.2, decreasing at higher molar ratios (Fig. 
3a,b). CD spectra taken when MT was added briefly to the pellet after filament assembly showed that the 
300/250 nm peaks were more prominent in reducing than in non-reducing conditions (Fig. S2b).  
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Coomassie-stained gels of dGAE incubated with MT under reducing conditions during assembly showed 
a marked loss of protein in the pellet at tau:MT molar ratios greater than 1:0.1, with elimination of the 
predominant 12 kDa monomeric species from the pellet, and transfer to the supernatant. At above 1:0.1 
molar ratio, the 24 and 48 kDa species became weak and then absent from both pellet and supernatant 
(Fig. 3c). 
  
At the threshold molar ratio of 1:0.1, distinctive oval structures were observed by TEM. Interestingly, 
these oval particles were generally seen only in samples that also produced the 300/250 nm CD peaks. As 
the concentration of MT was increased, these oval structures disappeared, and the only structures evident 
on the grid were small spherical particles (Fig. 3d). At higher magnification, the small spherical particles 
were amorphous in appearance, ranging 2 – 20 nm in size. In order to characterise them further, single 
particle analysis was used classify particles formed at a tau:MT ratio of 1:5 under reducing conditions.  
Single particle averaging revealed that the assemblies fitted into at least 11 distinct morphological classes, 
but heterogeneity of the samples did not allow for further structural analysis (Fig. S3). 
 
X-ray fibre diffraction was used to investigate whether MT at low concentrations altered the molecular 
architecture of the filaments. Filament formation was entirely prevented above a tau:MT molar ratio of 
1:0.6. At lower ratios (1:0.1, 1:0.2) the diffraction patterns were similar to those reported previously for 
untreated filaments [28]. At 1:0.4, it was possible to obtain a diffraction film in which there was good 
alignment of the remaining filaments. These produced meridional and equatorial diffraction signals at 4.7 
Å and 9.5 Å indicating retention of the underlying cross-β architecture  (Fig. S4). 
 
Assembly of the dGAE-C322A variant in the presence of MT in non-reducing conditions  
We have shown previously that the dGAE-C322A variant lacking cysteine has a greater propensity to 
form PHFs than the native form [28]. As with the native form, the variant incubated in non-reducing 
conditions in the presence of MT showed an MT-concentration-dependent reduction in β-sheet in the CD 
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spectrum from the pellet accompanied by concentration-dependent peaks at 300/250 nm which were 
maximal at a dGAE-C322A : MT molar ratio of 1:5. The CD spectrum of the supernatant showed weak 
random coil signal which did not change with increasing concentrations of MT (Fig. 4a,b).  
 
The corresponding SDS-PAGE gels showed that the protein was present predominantly in the pellet as a 
species with 12-kDa mobility, with a small amount of dimer migrating at 24 kDa. As shown previously 
[28], the species remaining in the supernatant had a gel mobility of 10 kDa. As the concentration of MT 
increased, there was more 12 and 24 kDa material in the pellet, as well as the appearance of higher order 
oligomers (Fig. 4c). 
  
TEM showed the presence of the same oval particles and filaments seen with the native form in the 
presence of MT at all protein:MT molar ratios (1:0.1 – 1:5.0) in non-reducing conditions. Higher 
magnification TEM showed that the particles were again composed of short, tightly packed filaments.  
Increasing the concentration of MT produced further aggregation and elongation of the oval particles 
(Fig. 4d).  
 
Assembly of the dGAE-C322A variant in the presence of MT in reducing conditions 
Following assembly of the dGAE-C322A variant in reducing conditions without MT, the CD spectrum of 
the pellet showed the characteristic β-sheet peak at 205 nm and a shifted trough at around 230nm [28]. 
When MT was present during assembly, there was a marked reduction in the β-sheet peak in the material 
in the pellet, and a corresponding increase in random coil in the material remaining in the supernatant. 
Unlike the native form, there were minimal 250 and 300 nm peaks in the pellet after 24 hours. (Fig. 5a,b)  
However, when MT was added briefly to the pellet from preformed dGAE-C322A filaments (Fig. S1d), 
the 300 nm peak was more intense than in a similar preparation in non-reducing conditions. (Fig. S1c)  
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The corresponding SDS-PAGE gels showed a biphasic transition. Without MT, the majority of protein (at 
12 and 24 kDa) was found in the pellet. At a protein:MT molar ratio of 1:0.1, there was increased protein 
in the supernatant. The protein remaining in the pellet migrated at 12 kDa, with an accompanying regular 
ladder extending to 60 kDa in multiples of 12 kDa. At higher molar ratios of MT, the pellet was largely 
eliminated with protein transferred to the supernatant. The supernatant species had the 12-kDa mobility 
normally associated with sedimenting fractions [28]. (Fig. 5c) 
 
dGAE-C322A forms PHF-like filaments in the presence of DTT very similar to those in non-reducing 
conditions [28]. The major structures found by TEM at a protein:MT molar ratio of 1:0.1 were the oval 
particles (Fig 4d). Given their unusual appearance, they were examined further by immunogold TEM 
using an antibody against total tau to confirm that these assemblies are composed of tau protein and are 
not artefacts. The short closely-packed fibrils were immunopositive for tau (Fig S5). At higher molar 
ratios, only the small spherical particles ranging in size from 2 – 20 nm were observed. These are similar 
to those formed by native dGAE in the presence of MT (Fig. 4d). A control was performed using the 
same total tau antibody but with amyloid- (1-42) fibrils. This did not show any non-specific labelling. 
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Discussion 
 
We have reported recently that dGAE, the core tau unit of the PHF (residues 297 – 391), assembles 
spontaneously in vitro into filaments that closely resemble native PHFs morphologically [28]. 
Spontaneous fibrillisation occurs in physiological conditions and without exogenous polyanionic 
reagents. These synthetic PHFs display a characteristic β-sheet structure by circular dichroism and fibre 
X-ray diffraction analysis. Reducing conditions enhance the assembly of dGAE into PHFs. A cysteine to 
alanine variant also self-assembles to form PHFs, indicating that disulphide cross-linking is unnecessary 
for filament assembly [28]. We now reveal that the MT moiety is significantly more effective in blocking 
PHF assembly under reducing conditions. CD spectra showed a dose-dependent reduction in the 
generation of β-sheet secondary structure in a low-speed pellet and a corresponding increase in random 
coil in the supernatant. SDS-PAGE gels showed a dose-dependent reduction in protein in the pellet and a 
transfer to the supernatant. Finally, filaments observed using TEM were eliminated and replaced by a 
population of small spherical particles. These effects were seen using both wild-type dGAE and the 
C322A variant. Therefore, the inhibitory effect of the MT moiety on the fibrillisation of the PHF core tau 
unit is not mediated via cysteine oxidation.  
 
When MT was incubated with dGAE under non-reducing conditions, the effect was partial. Although 
there was a dose-dependent reduction in β-sheet in the pellet and a corresponding increase in random coil 
in the supernatant, this was not associated with a transfer of protein from pellet to supernatant. On SDS-
PAGE gels the 12-kDa monomer and higher order oligomers became more prominent in the pellet with 
increasing concentrations of MT, particularly for the C322A variant. There was no clear effect of MT on 
the appearance of filaments seen by electron microscopy. The effect of MT on assembly in non-reducing 
conditions was largely the same whether the native dGAE fragment or the C322A variant was used. 
These results show that inhibition of PHF assembly by the MT moiety requires reducing conditions for 
optimal efficacy.   
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The question arises, therefore, whether the enhancement of the inhibitory effect of MT in reducing 
conditions is due to an effect on the dGAE species decreasing its propensity to fibrillise, or an effect on 
the MT moiety. As noted above, dGAE filament assembly is facilitated in reducing conditions. Therefore, 
reducing conditions must enhance the inhibitory efficacy of the MT moiety itself. The MT moiety can 
exist in oxidised (MT
+
) or reduced (LMT) forms depending on the pH and reducing potential of the 
milieu. DTT is available in 10-100 fold molar excess relative to MT in the reducing conditions used, and 
we have confirmed by a combination of UV spectroscopy and mass spectrometry that the LMT form is 
the major species present in these conditions. We conclude that LMT is the active moiety required for 
inhibition of aggregation of the PHF-core tau unit and that it does so in a cysteine-independent manner. 
 
We have shown previously that the dGAE monomer exists in two different conformations with mobilities 
of 12 kDa or 10 kDa on SDS-PAGE gels. Only the 12-kDa species is assembly competent as it is 
selectively enriched in the pellet fraction, whereas the 10-kDa species remains in the supernatant where it 
retains a random coil conformation. These gel mobility and differential sedimentation properties are 
independent of the cysteine residue at position 322 and are not altered by introducing DTT during 
assembly. As described in greater detail previously [28], PHFs assembled in vitro have the same detailed 
morphological features as PHFs isolated from AD brain tissue, implying that they are assembled from a 
similar underlying C-shaped subunit. This C-shaped subunit has been elucidated as a folded hairpin 
configuration of PHF core tau unit in AD PHFs [7]. This suggests that the distinctive 12-kDa gel mobility 
of the assembly-competent unit reflects the same folded hairpin conformation. Since it is specifically this 
species that is transferred to the supernatant when assembly is conducted in the presence of LMT, the 
inhibitory effect appears to interfere with the assembly competence of the core tau hairpin rather than 
conversion to the 10-kDa form. Further immunochemical and computational chemistry studies are 
required to determine the structural basis of this change in assembly competence.  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
The present findings shed some further light on the mechanism of LMT inhibition of PHF assembly. We 
show that an intermediate tau-LMT complex is formed at the threshold molar ratio of 1:0.1 which is 
insufficient to block PHF assembly completely, but gives rise instead to an oval particle consisting of 
short, closely packed tau fibrils. These oval particles are associated with the appearance of new MT-
dependent CD peaks at 300/250 nm. When MT was added briefly following filament assembly, the 
300/250 nm peaks were more evident in reducing than in non-reducing conditions. These findings 
indicate that LMT rapidly forms a concentration-dependent complex with the core tau unit which at a 
tau:MT molar ratio greater than 1:0.1 renders it assembly incompetent. This association appears to have 
greater inhibitory efficacy if the tau unit lacks a cysteine residue at position 322. In contrast to evidence 
from TEM and SDS-PAGE gels of supernatant and pellet fractions, the MT moiety was able to interfere 
with the β-sheet CD signal in the pellet in all the conditions studied. Insofar as the β-sheet signal 
originates from hairpin stacking, this suggests that the MT moiety is able to form an association sufficient 
to disturb this even in non-reducing conditions. However, this association is not sufficient in the absence 
of an adequate concentration of LMT to prevent PHF assembly and redistribute protein into the 
supernatant. 
 
Our results are at odds with the findings from studies based on heparin-induced fibrillisation of repeat-
domain tau fragments known as K19 and K18. The dGAE core tau unit is the product of a specific tau-tau 
association that templates further truncation which reproduces the proteolytically stable unit in a prion-
like fashion [19, 21]. The K19 fragment does not conform to this template and its assembly properties are 
quite different from those of the PHF core tau unit. Most notably, there is a 60% reduction in tau 
aggregation in reducing conditions, and the further inhibitory effect of the MT moiety in these conditions 
is minimal and evident only at a protein:MT ratio of 1:100 [26]. NMR evidence of a cysteine-dependent 
association between the MT moiety and full-length tau in a random coil configuration between residues 
280 and 330 in non-reducing conditions is also unlikely to have relevance to the cysteine-independent 
inhibitory effects we describe. Likewise, the fact that inhibitory activity is evident in the absence of a 
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cysteine residue implies that intramolecular disulphide link formation within the K18 fragment is also 
irrelevant to understanding the mechanism of action of the MT moiety on PHFs [23, 26]. More generally, 
our results suggest that the use of the heparin-induced filament assembly model as a basis for discovering 
novel tau aggregation inhibitors may produce misleading results.  
 
Although we have used spontaneous assembly of the truncated PHF-core unit as a model system to 
understand better the mechanism of action of the MT moiety, this should not be taken as implying that tau 
protein is truncated prior to aggregation. Indeed, we have shown in previous work that the key assembly 
events are likely to occur in a context of phase asymmetry as regards solid and aqueous phases, and that 
these most likely involve the capture of full-length tau in from aqueous phase [19, 32]. We have also 
show that a prior high affinity binding interaction through the repeat domain defines the proteolytically 
stable footprint that corresponding to the PHF-core tau unit [21, 33].   
  
On the basis of the cysteine oxidation hypothesis derived from results using the K19 and K18 fragments 
in vitro, Crowe and colleagues argue that MT would be predicted to be relatively ineffective as a tau 
aggregation inhibitor in vivo because its effect is blunted in a reducing environment [23]. Our results, on 
the contrary, demonstrate that the MT moiety is optimally effective in a reducing environment. We have 
shown previously that the MT moiety is effective as a tau aggregation inhibitor both in cells and in 
transgenic mouse models [20, 22]. The molar ratio at which the MT moiety becomes effective as an 
inhibitor of PHF assembly, i.e. 1:0.1, is approximately the same as that required to reverse the proteolytic 
stability of PHFs isolated from AD brain tissues [20, 21]. The evidence we have presented showing that 
LMT is the active moiety at the site required for inhibition of aggregation of the core tau unit of the PHF 
may be part of the explanation for the clinical evidence suggesting that the stable reduced form of the MT 
moiety (LMTM, hydromethylthioninium mesylate), appears to be effective at a dose 20-fold lower than 
the minimum effective dose previously identified using the oxidised MT
+
 form [19, 34]. A global clinical 
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trial is currently ongoing which aims to confirm that LMTM monotherapy at a dose of 8 mg/day is 
effective in delaying to the progression of early AD. 
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Materials and methods 
 
Truncated tau (dGAE) preparation  
Recombinant truncated dGAE tau and dGAE-C322A were expressed in bacteria and purified by P11 
phosphocellulose chromatography as described previously [21, 35], with minor modifications.  In some 
cases, 2-(N-morpholino)ethanesulfonic acid (MES), pH 6.25, was used instead of piperazine-N,N'-
bis(ethanesulfonic acid) (PIPES) and the protein was heat treated [36] instead of DE52 ion-exchange 
treatment prior to P11 chromatography. Protein fractions were eluted with buffer (50 mM PIPES, pH 6.8 
or 50 mM MES, pH 6.25, both supplemented with 1 mM EGTA, 5 mM EDTA, 0.2 mM MgCl2, 5 mM 2-
mercaptoethanol) containing 0.1-1 M KCl.  The peak of protein elution was identified by protein assay (at 
0.3-0.5 M KCl) and dialysed against either 80 mM PIPES buffer, pH 6.8, 1 mM EGTA, 5 mM EDTA, 0.2 
mM MgCl2, 5 mM 2-mercaptoethanol or phosphate buffer (10 mM; pH 7.4). Protein concentration, 
measured using Advanced Protein Assay Reagent (Cytoskeleton, Inc.) with bovine serum albumin as a 
standard, was in the range 2.7-4.9 mg/ml. The protein was diluted in phosphate buffer (10 mM; pH 7.4) at 
a range of concentrations (100 - 400 μM) for further analysis.  
 
Methylthioninium chloride (MTC) 
Methylthioninium chloride (MTC) was provided by TauRx Therapeutics Ltd. The concentrations are 
expressed as free methylthioninium base (MT). 
 
Assembly of dGAE and incubation with MTC 
dGAE (100 μM) was incubated at 37 C with agitation at 700 oscillations per min (Thermomixer C, 
Epppendorf, Germany) in the presence of MT at different molar ratios of dGAE to MT (1:0.1, 1:0.5, 1:1, 
1:2, 1:5 and 1:10) for 24h. To investigate the inhibition of dGAE and C322A variant assembly by MT 
under reducing conditions, samples were incubated either with and without DTT (10 mM) prior to 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
agitation. The assembly process was monitored using circular dichroism spectrometry (CD), negative 
stain transmission electron microscopy (TEM), X-ray fibre diffraction (XRFD), and SDS-PAGE. 
To investigate the minimal molar ratio required for inhibition, dGAE (100 μM) were incubated using the 
same assembly conditions in the presence of MT at different molar ratios of dGAE:MT (1:0.02, 1:0.05, 
1:0.1, 1:0.2, 1:0.4, 1:0.6, 1:0.08 and 1:1) for 24 h under reducing conditions.  
 
Transmission electron microscopy (TEM) 
Electron microscopy grids were prepared by placing 4 μl of sample onto formvar/carbon-coated 400-
mesh copper grids (Agar Scientific), blotting excess and then washing with 4 μl of 0.22 μM filtered milli-
Q water. Uranyl acetate (4 μL of 2% w/v) was placed on the grid once for one minute and then blotted 
and the grid allowed to air-dry. TEM projection images were collected using a JEOL JEM1400-Plus 
Transmission Electron Microscope operated at 120 kV equipped with a Gatan OneView camera (4kx4k). 
Images were recorded at 25 fps with drift correction using GMS3. 
 
Immunogold labelling transmission electron microscopy  
For all dilutions of antibodies and secondary gold probes a modified phosphate buffer saline (PBS, pH 
8.2) was used; this buffer was supplemented with BSA (1%), Tween-20 (0.005%), 10 mM Na EDTA, and 
NaN3 (0.2 g/l). dGAE-C322A (100 μM) was incubated with and without MT (10 μM) and incubated for 
24 h at 37 C with agitation at 700 oscillations per min in dark. Preformed fibrils were decorated ‘on grid’ 
using a polyclonal anti-tau antibody (Sigma-Aldrich, SAB4501831). In summary, 4 μl of dGAE-C322 
fibrils were pipetted onto Formvar/carbon coated 400-mesh copper TEM support grids (Agar Scientific, 
Essex, UK) and left for 1 min, then a filter paper was used to remove the excess. Normal goat serum (1.10 
in PBS, pH 8.2) was used for blocking for 15 min at room temperature. Grids were then incubated with 
(10 μg/ml IgG) rabbit anti-tau polyclonal antibody for 2 h at room temperature, rinsed three times for two 
minutes using PBS (pH 8.2), and then immunolabeled in a 10-nm gold particle-conjugated goat anti-
mouse IgG secondary probe (GaR10 British BioCell International, Cardiff, UK; 1.10 dilution) for 1 h at 
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room temperature. The grids were then rinsed five times for two minutes in PBS (pH 8.2) and rinsed five 
times for two minutes in distilled water. Finally, the grids were negatively stained using 0.5% uranyl 
acetate. As a negative control, Aß42 fibrils were examined using the same protocol.  
 
Circular dichroism spectrophotometry (CD) 
CD was performed using a Jasco Spectrometer J715 and spectra collected in triplicate at a maintained 
temperature of 21 °C.  Protein samples (60 μl) were placed into 0.2-mm path length quartz cuvettes 
(Hellma), and scanned from 180-350 nm.  Since the CD spectra were dominated by random coil signal, 
samples were separated by centrifugation at 20,000 x g for 15 min and 4 °C to isolate fibrillar structures 
from the mixture. CD was then determined on both supernatant and pellet fractions (40 μl) separately. CD 
data was presented in mdeg as the protein concentration is unknown and was not possible to measure due 
to interference of MT and DTT in standard protein assays. 
 
NanoDrop UV-vis spectroscopy 
UV-vis spectra were collected for 100 μM MT, 100 μM MT with 50 mM DTT (all prepared in 10 mM 
PB,pH 7.4), and 10 mM DTT. NanoDrop spectrophotometry was used.  
 
UV/Vis and Mass Spectrometry 
Volumetric solutions of MTC (1 mM, 100 µM and 10 µM) and DTT (10 mM, Sigma Aldrich) 
were prepared in phosphate buffer (pH 7.4, 10 mM, Merck). In addition a volumetric solutions 
MTC (1 mM) were prepared in; water, phosphate buffer (10 mM) without DTT, and with DTT 
(10 mM) in water without PB. Solutions were left a minimum of 1.5 hours prior to analysis but 
were observed to be stable for at least 48 hours. UV spectrometry was conducted on an 
Evolution 220 spectrophotometer (Thermo Scientific) running Insight software (version 1.4.40). 
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HRMS data was collected on a Xevo G2-QTof (Waters) running MassLynx software (version 
4.1). 
 
SDS-PAGE  
SDS-PAGE was conducted on the entire assembly mixtures as well as the supernatant and pellet fractions 
used for CD (3 μl of each per lane). Samples were mixed with SDS-PAGE sample buffer (without 
reducing agent) and separated using Any kDa Mini-Protean TGX Precast gels (Bio-Rad) at 120 V, 
until the sample buffer reached the end of the gel.  The gel was stained using Imperial Protein Stain 
(Thermo Scientific), following the manufacturer’s instructions, before sealing the gel and scanning on a 
Canon ImageRunner Advance 6055i scanner.  
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Figures 
Figure 1. Circular dichroism spectra of MT with heparin and DTT. CD spectra were collected using 
a 0.02cm path length cuvette. a) CD spectrum of 0.034 mg/ml of Heparin with 0.33 mM MT showing 
strong CD signals arising from ordering of the MT with heparin b) 0.034 mg/ml of Heparin alone, c) 10 
mM DTT in 10 mM phosphate buffer, pH 7.4 d) 0.5 mM of MT was incubated with and without 10 mM 
DTT in 10 mM phosphate buffer, pH 7.4 for 24 h at 37 °C with 700 oscillations per min agitation in the 
dark. Panels b, c and d confirm there is no CD signal arising from MT alone, DTT alone, or MTC plus 
DTT. 
Figure 2. MT-treated dGAE under non-reducing conditions. dGAE (100 μM) was incubated with MT 
at different molar ratios in phosphate buffer (10 mM; pH 7.4) for 24 h at 37  C, with agitation at 700 rpm 
in the dark. At 24 h incubation, the samples were separated by centrifugation for 15 mins at 4 ° C and 
20,000 x g. (a) CD spectra for the pellet; (b) CD spectra for supernatant, insert shows a graphical 
representation of relative intensity at 200 nm against dGAE:MTC ratio where 1:0 intensity is 100 %; (c) 
Coomassie-stained gel of non-reducing SDS-PAGE of separated supernatant (S) and pellets (P) at 
dGAE:MT ratios as shown.d)Transmission electron micrographs of negatively stained dGAE (100 μM) 
incubated for 24 h at 37 °C with MT at different molar ratios for dGAE:MT, in the absence DTT (10mM) 
from 0 h. Scale bars, 200nm. 
 
Figure 3. MT-treated dGAE under reducing conditions. dGAE (100 μM) was incubated with MT 
using different molar ratios in the presence of 10 mM DTT in 10 mM phosphate buffer (pH 7.4) for 24 h 
at 37  C and with 700 oscillations per min agitation in the dark. After 24 h incubation the samples were 
centrifuged for 15 mins at 4 ° C and 20,000 x g. The CD spectra were recorded for both (a) pellet and (b) 
supernatant; insert shows a graphical representation of relative intensity at 200 nm against dGAE:MTC 
ratio where 1:0 intensity is 100 %. (c) Coomassie blue-stained, non-reducing SDS-PAGE gel of separated 
supernatant (S) and pellet (P) fractions of dGAE (100mM) incubated with different ratios of dGAE:MT as 
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shown. d)Transmission electron micrographs of negatively stained dGAE (100 μM) incubated for 24 h at 
37 °C with MT at different molar ratios for dGAE:MT, in the presence DTT (10mM) from 0 h. Scale 
bars, 200nm. 
 
Figure 4. Inhibition of assembly of dGAE-C322A in non-reducing conditions. C322A variant (100 
μM) was incubated with MT using different molar ratios in the absence of 10 mM DTT in 10 mM 
phosphate buffer (pH 7.4) for 24 h at 37  C and with 700 oscillations per min agitation in the dark. After 
24 h incubation the samples were centrifuged for 15 mins at 4 ° C and 20,000 x g. The CD spectra were 
recorded for both (a) pellet and (b) supernatant; insert shows a graphical representation of relative 
intensity at 200 nm against dGAE:MTC ratio where 1:0 intensity is 100 %. (c) Coomassie blue-stained, 
non-reducing SDS-PAGE gel of separated supernatant (S) and pellet (P) fractions of dGAE (100mM) 
incubated with different ratios of dGAE:MT as shown. d)Transmission electron micrographs of 
negatively stained dGAE (100 μM) incubated for 24 h at 37 °C with MT at different molar ratios for 
dGAE:MT, in the absence DTT (10mM) from 0 h. Scale bars, 200nm. 
 
Figure 5. Inhibition of assembly of dGAE-C322A by MT in reducing conditions.. C322A variant 
(100 μM) was incubated with MT using different molar ratios in the presence of 10 mM DTT in 10 mM 
phosphate buffer (pH 7.4) for 24 h at 37  C and with 700 oscillations per min agitation in the dark. After 
24 h incubation the samples were centrifuged for 15 mins at 4 ° C and 20,000 x g. The CD spectra were 
recorded for both (a) pellet and (b) supernatant; insert shows a graphical representation of relative 
intensity at 200 nm against dGAE:MTC ratio where 1:0 intensity is 100 %. (c) Coomassie blue-stained, 
non-reducing SDS-PAGE gel of separated supernatant (S) and pellet (P) fractions of dGAE (100mM) 
incubated with different ratios of dGAE:MT as shown. d)Transmission electron micrographs of 
negatively stained dGAE (100 μM) incubated for 24 h at 37 °C with MT at different molar ratios for 
dGAE:MT, in the presence DTT (10mM) from 0 h. Scale bars, 200nm. 
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Highlights:  
 Paired helical filaments (PHF) composed of tau form in Alzheimer’s disease. 
 PHF formation is a target for treatment.  
 Methylthioninium (MT) inhibits spontaneous assembly of a core tau unit into PHFs.  
 MT acts optimally in the reduced form as Leuco-MT (LMT) and not via cysteine oxidation.  
 LMT is effective at much lower doses than the oxidised form of MT in clinical trials.  
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